Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever
Leaves” or the “Company”), a leading multi-national
operator and licensed producer of pharmaceutical-grade
cannabinoids, today announced the signing of a supply agreement
with Ethypharm (“Ethypharm”), a European manufacturer and
distributor of pharmaceutical products, for the sale of medical
cannabis extracts produced in Clever Leaves’ EU-GMP certified
facilities in Colombia. The initial portfolio of products includes
high-CBD, high-THC, and balanced CBD and THC formulations developed
exclusively by Clever Leaves to meet the regulatory needs of the
German market.
The products manufactured under this partnership will be sold
within Ethypharm’s branded portfolio and will expand Ethypharm’s
core product offering focusing on Central Nervous System (CNS)
diseases and conditions, chronic pain, and critical care
treatments. The portfolio will be sold in Germany through
Ethypharm’s local subsidiary, Ethypharm GmbH, and distributed
directly to pharmacies, where they will be dispensed to patients as
prescribed medicinal products.
“This partnership with Ethypharm, an established
European pharmaceutical company, advances our vision of providing
market-leading medical cannabis products to patients. Clever
Leaves’ focus on high-quality EU-GMP certified production and our
international supply chain has positioned us to develop, produce
and ship products to end-markets that will have significant impact
on patients’ treatments”, said Kyle Detwiler, CEO of Clever Leaves.
“Partnering with an established pharmaceutical company like
Ethypharm also allows Clever Leaves to more broadly enter the
German pharmaceutical market, which is currently considered one of
the most important international medical cannabis markets due to
its size, pace of growth, and Germany’s clinical credibility in
terms of paving the way to entering additional European or
international pharmaceutical markets.”
"Partnering and working with physicians and
pharmacists to improve people’s lives is one of Ethypharm’s daily
ambitions. Today, providing medical cannabis will answer a clear
unmet medical need for patients who are not relieved with current
treatments. This innovative collaboration on medical cannabis with
Clever Leaves is a good example of how Ethypharm has developed new
ways to provide patients with the care they need.” said Bertrand
Deluard, CEO of Ethypharm.
Clever Leaves boasts multiple international
certifications including a Good Manufacturing Practices (GMP)
Certification by INVIMA; Good Agricultural and Collecting Practices
(GACP) Certification; and European Union Good Manufacturing
Practices (EU GMP) Certification.
Ethypharm, was recently awarded a role in the
French cannabis experiment in a partnership with Aurora.
About Clever Leaves Holdings
Inc.Clever Leaves is a multi-national cannabis company
with an emphasis on ecologically sustainable, large-scale
cultivation and pharmaceutical-grade processing as the cornerstones
of its global cannabis business. With operations and investments in
the United States, Canada, Colombia, Germany and Portugal, Clever
Leaves has created an effective distribution network and global
footprint, with a foundation built upon capital efficiency and
rapid growth. Clever Leaves aims to be one of the industry’s
leading global cannabis companies recognized for its principles,
people, and performance while fostering a healthier global
community. Clever Leaves has received multiple international
certifications that have enabled it to increase its export and
sales capacity from its Colombian operations, including European
Union Good Manufacturing Practices (EU GMP) Certification, a Good
Manufacturing Practices (GMP) Certification by Colombia National
Food and Drug Surveillance Institute - Invima, and Good
Agricultural and Collecting Practices (GACP) Certification. Clever
Leaves was granted a provisional license in Portugal from Infarmed
– the Portuguese health authority – which allows Clever Leaves to
cultivate, import and export dry flower for medicinal and research
purposes. In addition, the Portuguese operation was recently
granted certification of compliance with GACP and IMC-GAP.
For more information, please
visit https://cleverleaves.com/en/home/ and
follow us on LinkedIn.
About the Ethypharm
GroupEthypharm is a European pharmaceutical company
focused on two therapeutic areas: the Central Nervous System and
Critical Care. Ethypharm markets its drugs directly in Europe and
China, and with partners in North America and the Middle East where
its drugs are in high demand. The Group employs more than 1,500
people, mainly in Europe and China. Ethypharm works closely with
authorities and healthcare professionals to ensure the appropriate
use of and access to its medicines, by as many people as
possible.
For more information visit www.ethypharm.com and
follow on LinkedIn.
Forward Looking StatementsThis
Press Release includes certain statements that are not historical
facts but are forward-looking statements for purposes of the safe
harbor provisions under the United States Private Securities
Litigation Reform Act of 1995. Forward-looking statements generally
are accompanied by words such as “anticipate,” “believe,”
“continue,” “estimate,” “expect,” “forecasts,” “future,” “intend,”
“may,” “outlook,” “plan,” “predict,” “potential,” “projected,”
“seek,” “seem,” “should,” “will,” “would” and similar expressions
(or the negative versions of such words or expressions) that
predict or indicate future events or trends or that are not
statements of historical matters. Such forward-looking statements
are subject to risks and uncertainties, which could cause actual
results to differ from the forward-looking statements. Factors that
may cause such differences include, without limitation,
expectations with respect to future operating and financial
performance and growth, including if or when Clever Leaves will
become profitable; Clever Leaves’ ability to execute its business
plans and strategy and to receive regulatory approvals; potential
litigations; global economic conditions; geopolitical events,
natural disasters, acts of God and pandemics, including, but not
limited to, the economic and operational disruptions and other
effects of COVID-19; regulatory requirements and changes thereto;
access to additional financing. The foregoing list of factors is
not exclusive. Additional information concerning certain of these
and other risk factors is contained in Clever Leaves’ most recent
filings with the SEC. All subsequent written and oral
forward-looking statements concerning Clever Leaves and
attributable to Clever Leaves or any person acting on its behalf
are expressly qualified in their entirety by the cautionary
statements above. Readers are cautioned not to place undue reliance
upon any forward-looking statements, which speak only as of the
date made. Clever Leaves expressly disclaims any obligations or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in its expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Clever Leaves Press contacts:McKenna
Miller KCSA Strategic
Communications +1347-487-6197mmiller@kcsa.com
Diana SigüenzaStrategic Communications
Director+57310-236-8830Diana.siguenza@cleverleaves.com
Clever Leaves Investor inquiries: Sean
Mansouri, CFA or Cody SlachGateway Investor
Relations+1949-574-3860CLVR@gatewayir.com
Clever Leaves Commercial inquiries:Andrew
MillerVice President Sales - EMEA, North America, and
Asia-Pacific+1416-817-1336andrew.miller@cleverleaves.com
Ethypharm Media Contacts:Avril PONELLE+ 33 (0)1
41 12 17 20presse@ethypharm.com
Markus GLADBACH / Christine VOGL-KORDICK+49 157 71 44 60 98 /
+49 172 86 50 982presse@thecommsduo.com
Clever Leaves (NASDAQ:CLVR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clever Leaves (NASDAQ:CLVR)
Historical Stock Chart
From Apr 2023 to Apr 2024